TICKERNOMICS Sign up
Last Update: 2024-12-27 15:28:26
Allovir Inc. ( ALVR ) https://www.allovir.com
0.47USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-30.43%
ALVR
SPY
32.66%
-96.44%
ALVR
SPY
108.59%
ALVR
0.00%
SPY
302.52%
ALVR
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
51.93
-60.92
0.08
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.52
6.08
0.43
-143.31
0.00
1.19
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-385.43
98.32
-152.76
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-41.25
-24.82
0.00
Other Earnings and Cash Flow Stats:
Allovir Inc. ( ALVR ) Net Income TTM ($MM) is -100.20
Allovir Inc. ( ALVR ) Operating Income TTM ($MM) is -89.63
Allovir Inc. ( ALVR ) Owners' Earnings Annual ($MM) is 0.00
Allovir Inc. ( ALVR ) Current Price to Owners' Earnings ratio is 0.00
Allovir Inc. ( ALVR ) EBITDA TTM ($MM) is -89.26
Allovir Inc. ( ALVR ) EBITDA Margin is -152.76%
Capital Allocation:
Allovir Inc. ( ALVR ) has paid 0.00 dividends per share and bought back -1.505328 million shares in the past 12 months
Allovir Inc. ( ALVR ) has reduced its debt by 23.885 million USD in the last 12 months
Capital Structure:
Allovir Inc. ( ALVR ) Interest-bearing Debt ($MM) as of last quarter is 9
Allovir Inc. ( ALVR ) Annual Working Capital Investments ($MM) are 20
Allovir Inc. ( ALVR ) Book Value ($MM) as of last quarter is 121
Allovir Inc. ( ALVR ) Debt/Capital as of last quarter is 7%
Other Balance Sheet Stats:
Allovir Inc. ( ALVR ) has 116 million in cash on hand as of last quarter
Allovir Inc. ( ALVR ) has 1 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Allovir Inc. ( ALVR ) has 115 common shares outstanding as of last quarter
Allovir Inc. ( ALVR ) has 0 million USD of preferred stock value
Academic Scores:
Allovir Inc. ( ALVR ) Altman Z-Score is 14.18 as of last quarter
Allovir Inc. ( ALVR ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Allovir Inc. ( ALVR ) largest shareholder is owning shares at 0.00 ($MM) value
Hagen Brett R(an insider) Sold 554 shares of Allovir Inc. ( ALVR ) for the amount of $303.87 on 2024-11-19
49.12% of Allovir Inc. ( ALVR ) is held by insiders, and 42.95% is held by institutions
Allovir Inc. ( ALVR ) went public on 2020-07-30
Other Allovir Inc. ( ALVR ) financial metrics:
FCF:-94.98
Unlevered Free Cash Flow:0.00
EPS:-0.14
Operating Margin:-385.43
Gross Profit Margin:98.32
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-13.63
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Allovir Inc. ( ALVR ) :
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.